*Corresponding Author:
D. D. Gadade
Shri Bhagwan College of Pharmacy, CIDCO N-6, Aurangabad-431 003
E-mail: [email protected]
Date of Submission 04 August 2016
Date of Revision 27 December 2016
Date of Acceptance 20 March 2017
Indian J Pharm Sci 2017;79(2):277-286  


An attempt was made to improve the solubility and physicochemical properties of the poorly soluble lornoxicam by crystal engineering with different coformers. Nineteen different coformers were screened during this study. Cocrystals were prepared by neat grinding method. The prepared cocrystals were evaluated for solubility, powder characteristics, assay and in vitro dissolution study. The solid state property was characterized by differential scanning calorimetry, Fourier transform infrared spectroscopy, powder X-ray diffraction analysis and Raman spectroscopy. Maximum solubility and dissolution rate were observed with cocrystal prepared using saccharin sodium. Cocrystallization leads to increased solubility and improved in vitro dissolution of lornoxicam.


Coformer, cocrystal, lornoxicam, solubility, dissolution, crystal engineering

The major challenge to the design of oral dosage forms lies with their poor bioavailability. The most common causes of low oral bioavailability are poor solubility and low permeability of active pharmaceutical ingredient (API) [1]. Multiple approaches have been adopted to improve the solubility of poorly water soluble APIs including micronization [2], complexation with cyclodextrins [3], cosolvency [4,5], solid dispersions [6], salt forms [7], nanoparticles [8] and surfactants [9], etc. Cocrystals are a class of multicomponent molecular crystals demonstrated to enhance the solubility, bioavailability and/or stability of API, which has been proposed as a unique crystal engineering approach to alter the physicochemical properties of compounds [10-12]. According to recently published guidance by the United States Food and Drug Administration (USFDA) cocrystals are defined as, ‘crystalline materials composed of two or more molecules within the same crystal lattice [13].

Lornoxicam (Figure 1) is a non-steroidal antiinflammatory drug (NSAID) of oxicam class with analgesic, antiinflammatory and antipyretic properties and its daily dose is 8 mg [14]. It belongs to Biopharmaceutical Classification System (BCS) - class II substance with low solubility and high permeability. It was reported to be practically insoluble in water and has low to variable bioavailability. The reported low aqueous solubility (0.0385±0.01 mg/ml) at ambient temperature impairs its dissolution in the upper gastric fluid, which alters bioavailability and hinders its therapeutic application and thereby onset of action or activity [15-17]. The problem of low solubility of a compound can be solved by crystal engineering approach while maintaining its stability. This research has two principle objectives; one to screen coformers through co-crystallization with lornoxicam to enhance its solubility and dissolution rate and the second to characterize and evaluate the selected cocrystal form of lornoxicam. In the current study 19 different coformers were screened to prepare lornoxicam cocrystals by neat grinding method. The cocrystals with optimum solubility were characterized using differential scanning calorimetry (DSC), Fourier transform infrared spectroscopy (FTIR), powder X-ray diffraction (XRD) analysis and Raman spectroscopy.


Figure 1: Lornoxicam chemical structure

Materials and Methods

Lornoxicam was received as a gift sample from Sun Pharmaceutical Ltd., Vadodara, India. Sodium saccharin and all other coformers were procured from Research Fine Lab., Mumbai. All other materials used in the study were of analytical grade. A digital melting point apparatus (Chief Scientific), Roche friability test apparatus (VFT-2D, Veego Instruments Corp.), dissolution test apparatus (VDA6DR, Veego Instruments Corp.), ultraviolet spectrophotometer (UV- 1800, Shimadzu), Fourier transform spectrophotometer (Thermo Fischer Scientific), differential scanning calorimeter (DSC, Mettler Toledo), powder X-ray diffractometer (Panalytical's X'Pert Pro) and FTRaman spectrometer (Bruker RFS 27) were utilized for characterization of raw materials and the evaluation of formulations under study. The tablet compression machine (Karnavati Engineering), was used for direct compression of tablets.

Preparation and evaluation of cocrystals:

Lornoxicam cocrystals were prepared using the API and coformer in 1:1 M stoichiometric ratio by neat grinding method. The mixtures were then ground for 20 min in an agate mortar with a pestle. The milling time was kept short to avoid any degradation of the materials [18,19]. The melting point of raw materials and cocrystals were determined by the capillary method. In this methodology, a thin glass capillary tube containing the substance to be determined was introduced into a heated stand (liquid paraffin) in close proximity to a high accuracy thermometer. The temperature in the heating stand was raised at a fixed rate until the sample in the tube transitioned into the liquid state [19]. Drug content was estimated by dissolving weighed quantities of cocrystals in 5% w/v aqueous N,Ndimethylformamide in triplicate. The solutions were filtered and diluted appropriately and samples were analysed spectrophotometrically at λmax 378 nm.

Shake flask method was employed for the aqueous solubility measurements, performed in triplicates by Higuchi and Connors method [20]. An excess amount of cocrystals were added to the flask containing distilled water. The solutions were vortexed for 2 min and placed on a rotary shaker at 100 rpm and 27±0.5° for 24 h. After equilibrium, the solution was filtered through Whatman filter paper (#41) and the concentration of drug was determined spectrophotometrically at λ 378 nm [21].

The prepared cocrystals were evaluated for various flow property parameters like bulk density (BD), tapped density (TD), Carr’s index (CI), Hausner’s ratio (HR) and the angle of repose (AR). AR was measured using the fixed funnel method [22]. The partition coefficient of the API and lornoxicam-saccharin sodium cocrystals were determined in octanol/water and octanol/ phosphate buffer pH 7.4 systems. The study was performed in triplicate [23].

The FTIR spectra of lornoxicam and optimized batch of cocrystals were obtained on the FTIR using the KBr disk method and the scanning range was in between 4000-660 cm-1 [24]. Raman spectroscopic analysis is a spectroscopic technique used to study vibrational, rotational and other low frequency modes in a system, which has been demonstrated to be a powerful tool for distinguishing is the structural phase. There are many applications using Raman spectroscopy to identify characteristic peaks of cocrystal products. The analysis of optimized cocrystals was performed using FTRaman spectrometer [25].

Powder XRD pattern of lornoxicam and optimized batch of cocrystals were recorded using powder X-ray diffractometer and using Cu-kα radiation. The diffractometer was run at a scanning speed of 2°/min and a chart speed of 2°/2 cm per 2θ. DSC of lornoxicam and optimized batch of cocrystals were done using DSC, at a heating rate of 10°/min in the range 50° to 300° under the nitrogen atmosphere [26].

Formulation and evaluation of tablets:

Conventional immediate release tablets of lornoxicamsaccharin sodium cocrystals were prepared by direct compression technique. The batches were prepared by 22 factorial experimental designs [19]. Formulae for 4 experimental batches were given in Table 1. The prepared tablets of cocrystals were evaluated for uniformity of weight, hardness and friability. The hardness was determined by using Veego hardness tester, where the force required to break the tablet was noted. Uniformity of weight was determined by weighing 20 tablets individually and calculating the average weight and comparing the individual tablet weight to the average value. The friability of the tablets was determined using Veego friabilator [27].

Ingredients P1 (g) P2 (g) P3(g) P4 (g)
Lornoxicam-sodium saccharin
13.27 13.27 13.27 13.27
Microcrystalline cellulose PH 101 180.73 166.73 178.73 168.73
Magnesium stearate 2.0 4.0 4.0 2.0
Sodium starch glycolate 4.0 16.0 4.0 16.0
Total weight 200.00 200.00 200.00 200.00

Table 1: Experimental batches

In vitro dissolution studies:

In vitro dissolution studies of tablets was performed using USP apparatus type II (Veego) fitted with the paddle (50 rpm) at 37±0.5° using phosphate buffer pH 7.4, and water 900 ml as a dissolution medium. Aliquot of 5 ml samples were withdrawn, at an interval of every 10 min to 60 min. The samples were filtered and assayed at λmax 378 nm using a UV 1800 double-beam spectrophotometer (Shimadzu). At each time point, after withdrawing the sample, an equal volume was replaced with fresh dissolution media. Prepared tablets of optimized cocrystals were compared with marketed product in terms of In vitro drug release study [28].

Stability studies:

Optimized formulation was subjected to stability studies at temperature 40º/75% relative humidity (RH) for a period of 1 mo. The optimized formulation sealed in aluminium foil was kept at the above mentioned temperature and humidity condition [29]. At the end of studies, samples were analysed for appearance, drug release in phosphate buffer pH 7.4, percent drug content, hardness and friability. Results of drug content and drug release studies of tablets under stability studies were analysed using the student’s t-test [30].

Results and Discussion

The melting point of API, coformers and cocrystals were as given in Table 2. Almost in all cocrystal batches melting point was different from API and coformers. There was no correlation between melting point of cocrystal and API/coformer. The transformed melting points of cocrystals may be assigned to the physical non-covalent interaction between drug and coformer, altered packing arrangement or change in the crystallinity of molecules [31].

The data for aqueous solubility profile of the API was shown in Figure 2. The solubility of cocrystals in distilled water was shown in Table 2. The maximum aqueous solubility was obtained with lornoxicamsaccharin sodium cocrystals (F18), which might have resulted from changes in the molecular attributes due to non-covalent interaction in cocrystals. Saccharin has been reported as typical coformer in the literature for improving solubility of the parent API and also to make sweet cocrystal owing its sweetening property [32,33]. The more hydrophilic nature of coformer as compared to the constituent drugs, and therefore such selective drug solubilisation is generally observed with solubilizing agents (coformer) in aqueous media [34]. Solubility is related to the crystal lattice energy within the solid state; there are various potential interactions within the crystal structure including hydrogen bonding and vander Waals interactions within cocrystals [35]. The solubility enhancement of lornoxicam in cocrystals with saccharin may be a result of lower lattice energy of cocrystals allowing the more facile crystal disruption by the solvent [36]. The solubility advantage of cocrystals could effectively translate to an improved absorption of the drug.

Formulation Drug/coformer MP of
drug/coformers (°)
MP of
cocrystals (°)
Average solubility API/cocrystal (µg/ml)
F1 Lornoxicam 225-230 - 22.690±2.05
F2 Benzoic acid 122.4 228 22.95±3.33
F3 Salicylic acid 157-159 185-190 11.10±2.33
F4 Malonic acid 135 280-285 26.35±1.13
F5 4-Hydroxy Benzoic acid 213-214 180-185 60.05±3.66
F6 Succinic acid 185-187 260-265 25.33±1.50
F7 Tartaric acid 168-170 193-196 21.87±2.00
F8 Fumaric acid 287 270-275 14.04±2.39
F9 Anthranillic acid 146-148 220-222 36.47±1.69
F10 Ascorbic acid 190-192 255-260 21.38±3.25
F11 Cinnamic acid 133 250-255 25.23±3.88
F12 PABA 187-187.5 223-225 64.12±1.33
F13 Hippuric acid 187-188 265-268 10.88±1.04
F14 Ferulic acid 174 190-195 71.04±2.44
F15 Glutaric acid 95-98 220-225 17.04±1.25
F16 Urea 133-135 235-240 55.09±1.66
F17 Resorcinol 109-111 245-250 47.89±2.30
F18 Saccharin sodium >300 245-250 156.05±1.33
F19 Citric acid 150 195-200 23.55±1.69
F20 Oxalic acid 101 200-205 43.06±1.06

Table 2: Solubility and melting point of cocrystals


Figure 2: pH solubility profile of lornoxicam image Solubility (μg/ml)

The BD and TD, the AR, CI, and HR were measured and presented in Table 3. It was observed that parameters indicating flow characteristics were significantly improved with lornoxicam-saccharin sodium cocrystals as compared to API. This result emphasized altered packing arrangement in cocrystal leading to improved micromeritic properties.

API/cocrystal Angle of repose (°)* Bulk density (gm/ml)* Tapped density (gm/ml)* Carr’s index (%)* Hausner’s ratio*
API 41.66±2.99 0.30 ± 0.02 0.52 ± 0.06 42.40 ± 1.29 1.73 ± 0.06
Cocrystal 26.72 ± 1.05 0.73 ± 0.05 0.91 ± 0.04 19.78 ± 1.12 1.24 ± 0.02

Table 3: Pre-Formulation characteristics of api and cocrystal

The partition coefficient (log P) of lornoxicam in octanol/water and octanol/buffer pH 7.4 was 2.13 and 1.91, respectively. It indicated that lornoxicam is hydrophobic in nature, which might be the reason for its poor aqueous solubility. The reported partition coefficient of lornoxicam is 1.8, as determined in n-octanol and phosphate buffer (pH 7.4) [37]. The partition coefficient (log P) of lornoxicam:saccharin sodium cocrystals was found to be 1.69 and 1.28, respectively in octanol/water and octanol/buffer pH 7.4 systems. This revealed the transformation of hydrophobic nature of lornoxicam to hydrophilic nature in cocrystal form.

FTIR is an important tool for prediction of cocrystal formation and it showed the hydrogen bond formation between API and the coformer. Important peaks seen were at -OH stretching, 3671.8 cm-1, -NH stretching aromatic, 3467.38 cm-1, -C=O ketone stretching, 1681.62 cm-1, S=O symmetric stretching, 1187.94 cm-1, S=O asymmetric stretching, 1342.21 cm-1, aromatic C-H stretching, 2938.98 cm-1, -Cl stretching, 794.52 cm-1 [38]. FTIR spectra of API, coformer and cocrystal were given in Figure 3. The alteration in peak shape at 3671.8 cm-1 and broadening at 2950.55 cm-1 indicated conjugation of the hydroxyl group with the aromatic alkyl function in lornoxicam, which might be assigned to non-covalent interaction in cocrystal. Weak interaction seen at 3467.38 cm-1 indicated the involvement of the secondary amine in lornoxicam.


Figure 3: FTIR spectrum of API, CCF and cocrystal
A. Lornoxicam; B. saccharin; C. lornoxicam-saccharin cocrystal

Raman spectroscopy has also been an imperative tool for predicting cocrystal formation demonstrating the hydrogen bond formation between the API and CCF. FT-Raman spectrum of the cocrystal was shown in Figure 4. Important peaks seen were C=N strong 1590.04 cm-1, C=O medium 1635.83 cm-1, C-S aromatic 1179.83 cm-1, CH3 medium 1382.81 cm-1, Cl strong 690.42 cm-1. The characteristics peaks of (O-H) at 3100-3650 cm-1 and (N-H) at 3300-3500 cm-1 were not observed in FT-Raman spectra indicated weak non-covalent bond formation. XRD patterns of drug and cocrystals were shown in Figure 5. The diffraction pattern of the API and cocrystals showed that both were crystalline in nature as demonstrated by numerous distinct peaks of 2θ. Powder XRD pattern of lornoxicam cocrystals indicates formation of new crystalline phases, which can be attributed to cocrystal formation [39,40].


Figure 4: Raman spectra of lornoxicam cocrystals


Figure 5: Powder X-ray diffractogram of lornoxicam (A) and lornoxicam-saccharin sodium cocrystal, 1:1 (B)

DSC analysis was employed to evaluate the phase of transformation during the formation of cocrystals. DSC thermogram of lornoxicam in Figure 6A showed an endothermic peak at 221.26° corresponding to its melting point. There was a shift in the drug peak in case of the cocrystals and a single peak was observed at 219.28° in Figure 6B. The strong non-covalent interaction between the API and the coformer generally led to the formation of cocrystals. This non-covalent physical interaction expected to be between an API and a coformer is due to hydrogen bond formation between polar functional groups. This interaction resulted in moderate to complete alterations in molecular arrangement of cocrystal formed, thus giving a new crystalline arrangement with altered physical properties including the melting point and/or the solubility. The formation of cocrystal was also confirmed on the basis of powder XRD studies, which indicated completely different diffractograms for cocrystals and lornoxicam. Thus the strength of hydrogen bonding will definitely influence the melting point characteristic of a cocrystal [41].


Figure 6: DSC thermograms of lornoxicam (A); lornoxicam-sodium saccharin cocrystals (B)

The evaluation results of immediate release tablet of lornoxicam cocrystal are shown in Table 4. The hardness of P4 batch was found to be 5.5±0.5 kg/ cm2. Uniformity of weight and friability were found to be within pharmacopoeia limits [42]. In vitro disintegration time was found to be not more than 24 s. The intrinsic dissolution rate (IDR) at the end of 60 min was 10.81±0.17 mg/cm2 and 12.73±0.26 mg/ cm2, respectively for lornoxicam and F18 cocrystal indicating cocrystal improved IDR. After performing the evaluation of experimental formulation batches 86.14±1.33% and 93.01±0.77% cumulative drug release was observed in distilled water and phosphate buffer pH 7.4, respectively with P4 batch. Hence, it was selected as optimized batch.

Batch Thickness (mm)* (n=3) Hardness (kg/cm2)* (n=3) In vitro disintegration time (min)*(n=3) Uniformity of weight (g)* (n=20) Friability (%)* (n=35)
P1 3.18 ± 0.03 5.8 ± 0.4 20 ± 4 0.20 ± 0.002 0.76 ± 0.30
P2 3.20 ± 0.02 5.6 ± 0.2 18 ± 2 0.20 ± 0.003 0.66 ± 0.31
P3 3.21 ± 0.03 5.5 ± 0.4 21 ± 1 0.20 ± 0.003 0.79 ± 0.20
P4 3.19±0.05 5.5 ± 0.5 20 ± 2 0.20 ± 0.002 0.66 ± 0.23

Table 4: Evaluation of all batches

The optimized formulation was compared with marketed tablets in the in vitro dissolution study in distilled water and phosphate buffer pH 7.4 shown in Figures. 7 and 8, respectively. Percent cumulative drug release was found to be 47.63±0.51% and 57.93±1.66% at the end of 60 min, respectively in distilled water and phosphate buffer pH 7.4 with marketed tablets (Lofecam, Sun Pharma). The percent cumulative drug release at the end of 60 min with P4 batch was 86.14±1.33% and 93.01±0.77% indicating improved dissolution of lornoxicam by co-crystallization.


Figure 7: Percent Cumulative Drug release of P1 to P4 batches and marketed tablet (Lofecam) in distilled water


Figure 8: Percent cumulative drug release of P1 to P4 batches and marketed tablet (Lofecam) in buffer pH 7.4 image

The 22 experimental factorial design was used in this study for optimization of variables magnesium stearate (A) and sodium starch glycolate (B) (SSG) for preparation of immediate release tablet formulations of lornoxicam: saccharin sodium cocrystal. The magnesium stearate was evaluated at 1% w/w and 2% w/w and SSG was evaluated at 2% w/w and 8% w/w concentration in the experimental design at -1 and +1 levels, respectively. There was minimal effect of magnesium stearate on drug dissolution but SSG can improve dissolution to a certain extent as it can be seen from the Eqns. given below and contour surface plots in Figure 9.


Figure 9: Contour surface plot for 22 factorial design for dissolution profile in distilled water (A); phosphate buffer pH 7.4 (B) image


Figure 10: Percent cumulative drug release of P4 batch tablets in phosphate buffer at pH 7.4 during stability studies

The response-drug release of lornoxicam from the immediate release tablets of cocrystal was determined at the end of 60 min in distilled water and phosphate buffer pH 7.4. The coded and uncoded Eqns. for the drug release were obtained from SPC package for MS-Excel and were as given below. Eqns for drug release in distilled water were coded: %DR = 82.140– 0.642 A+1.595 B–1.720 AB and Uncoded: %DR = 72.81+4.450×magnesium stearate+1.595×SSG– 1.720×magnesium stearate×SSG. Eqns. for drug release in phosphate buffer pH 7.4 were, coded: %DR = 87.249–0.744 A+3.363–1.461 AB and uncoded: %DR = 76.57+3.381×magnesium stearate+2.582×SSG– 0.974×magnesium stearate×SSG, where, %DR is percent cumulative drug release, (A) is magnesium stearate and (B) is SSG.

The addition of SSG can improve drug release while addition of magnesium stearate could decrease the drug release from formulation. SSG is hydrophilic carboxymethylated starch polymer, which act by rapid water uptake and its water uptake is higher at alkaline pH compared to acidic pH [43]. SSG takes up more than 20 times its own weight of water [44]. Hence, it showed faster swelling and disintegration of tablet assisting dissolution of the drug. Magnesium stearate is hydrophobic lubricant commonly used in small concentration but increasing its concentration in the formulation could decrease the drug release. The P-values for the percent cumulative drug release of lornoxicam:saccharin sodium co-crystals in distilled water and phosphate buffer at pH 7.4 were less than 0.05. Thus, the 22 experimental factorial designs can be utilized for evaluation effects of selected variables magnesium stearate and SSG on drug release. The factorial interactions of variables were diminishing the drug release of lornoxicam from formulation as exemplified in equations. Hence, concentration of magnesium stearate shall be kept low while SSG can be used at higher concentration to obtain optimum drug release from the tablet formulations.

The drug content, hardness, friability and disintegration time of P4 batch of tablet formulation was evaluated during stability studies. The outcomes of stability studies for P4 batch were as reported in Table 5. It reveals that the optimized formulation was quite stable at room temperature. The data of drug content and drug release in pH 7.4 buffer (at the end of 60 min) for P4-batch during stability studies was evaluated by Paired student’s t test using GraphPad Prism 5.0. There was no significant difference in drug content and percent cumulative drug release (Figure 10) of P4- batch formulation at 25±2° and RH 60±5% at the end of 30 d. The drug content and drug release (at the end of 60 min) in phosphate buffer for P4 formulation batch at accelerated condition 40°±2 and RH 75±5% shows the significant difference at the end of 30 d as evaluated by student’s t-test. Therefore, P4-batch of tablet formulation was found to be quite stable at room temperature than the accelerated condition.

Parameters Appearance Drug content (%)* In vitro disintegration time (min)* Hardness (kg/cm2)* Friability (%)*
Initial 25° ± 2° Yellow 99.77 ± 0.15 21 ± 1.5 5.5 ± 0.4 0.62 ± 0.39
After 15 d
40 ± 2°/RH 75 ± 5% Yellow 99.35 ± 0.33 20 ± 2.3 5.1 ± 0.5 0.58 ± 0.23
25 ± 2°/RH 60 ± 5% Yellow 98.95 ± 0.65 20 ± 2.5 5.2 ± 0.3 0.60 ± 0.09
After 30 d
40 ± 2°/RH75 ± 5% Yellow 98.52 ± 1.05 20 ± 2.5 5.0 ± 0.6 0.56 ± 0.43
25 ± 2°/RH60±5% Yellow 99.68 ± 0.12 21 ± 1.6 5.4 ± 0.2 0.69 ± 0.35

Table 5: Stability data of tablet formulation batch P4

The major problem associated with lornoxicam was its low solubility and there by high variability in bioavailability after oral administration. Therefore, it was necessary to enhance the solubility and dissolution rate of lornoxicam to obtain faster dissolution. This was achieved by formulating cocrystals of API by neat grinding method. Maximum solubility was obtained with saccharin sodium as a cocrystal former (1:1 stoichiometric ratio) along with improved dissolution rate. From the above discussion, it is clear that improvement in solubility and dissolution rate of lornoxicam can be achieved by cocrystals. In vitro dissolution of optimized lornoxicam cocrystal tablet was comparatively higher than API and marketed formulation, which reflect improvement in solubility. Thus, the corystals can work as an antique and multifaceted approach for improvement of solubility and dissolution with improvement in physicochemical properties of poorly water soluble drugs [45] like lornoxicam. From the current study, it was concluded that stable cocrystals of lornoxicam with saccharin sodium can be successfully prepared by crystal engineering approach with improved solubility and in vitro dissolution.


Authors thank the Sun Pharmaceuticals Ltd., Ahmedabad, India for providing drug as a gift sample.

Conflict of interest

The author (s) declares no conflict of interest.

Financial support and sponsorship